Sai Life Sciences Ltd
NSE:SAILIFE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
640.25
955.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Sai Life Sciences Ltd
Sai Life Sciences Ltd. operates as a contract research, development, and manufacturing organization. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2024-12-18. The firm carries out contract research and manufacturing activities for customers engaged in pharmaceutical and biotechnology industries. The company is engaged in offering a range of services tailor-made to the customer's requirements. The company provides discovery and chemistry, manufacturing, and controls (CMC) services that span from drug discovery to process development and early-phase supplies, all the way to commercial launch and life cycle management. Its services include Integrated Drug Discovery, Synthetic & medicinal chemistry, Biology, drug metabolism and pharmacokinetics (DMPK), Genotoxicity, General Toxicology and Computational chemistry. Its CMC services include route scouting; process development; analytical development; process safety; stability studies; early and mid-phase supplies; late phase, commercial manufacturing; technology transfer, and technologies.
Sai Life Sciences Ltd. operates as a contract research, development, and manufacturing organization. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2024-12-18. The firm carries out contract research and manufacturing activities for customers engaged in pharmaceutical and biotechnology industries. The company is engaged in offering a range of services tailor-made to the customer's requirements. The company provides discovery and chemistry, manufacturing, and controls (CMC) services that span from drug discovery to process development and early-phase supplies, all the way to commercial launch and life cycle management. Its services include Integrated Drug Discovery, Synthetic & medicinal chemistry, Biology, drug metabolism and pharmacokinetics (DMPK), Genotoxicity, General Toxicology and Computational chemistry. Its CMC services include route scouting; process development; analytical development; process safety; stability studies; early and mid-phase supplies; late phase, commercial manufacturing; technology transfer, and technologies.
Revenue Growth: Sai Life Sciences reported total H1 FY '26 revenue of INR 1,034 crores, up 53% year-on-year, with strong growth in both CRO and CDMO segments.
Margin Expansion: EBITDA margin improved to 27%, up 650 basis points, driven by operational efficiency and better utilization.
CDMO Strength: CDMO revenues rose 72% year-on-year, now making up 64% of total revenue, reflecting scale-up in late-stage and commercial programs.
Strategic Investments: The company continues significant CapEx, focusing on expanding capacity, R&D infrastructure, and advanced technology platforms in peptides, ADCs, and oligonucleotides.
Sustained Outlook: Management maintains confidence in sustaining 15%-20% revenue growth over the next 3–5 years, with a healthy project pipeline.
Cost Pressures: Other expenses increased sharply, partly due to one-time consulting fees for productivity and benchmarking projects.
Quality & Compliance: The company completed 35 customer and 3 regulatory audits in 12 months with zero critical observations, highlighting strong compliance and operational discipline.
